New insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease, and lymphoma

International Journal of Dermatology

Volumn 49, Issue 1, 2010, Pages 1-11

  Wang, Hui ^a   Yosipovitch, Gil ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTORPHANOL; C REACTIVE PROTEIN; CAPSAICIN; COLESTYRAMINE; DOXEPIN; GABAPENTIN; GASTRIN RELEASING PEPTIDE; HISTAMINE; HISTAMINE RECEPTOR; HYDROXYZINE; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 6; MIRTAZAPINE; NALFURAFINE; NALTREXONE; NERVE GROWTH FACTOR; OPIATE; PAROXETINE; PRAMOCAINE; PREGABALIN; PROTEINASE; RIFAMPICIN; SERTRALINE; TACROLIMUS; URSODEOXYCHOLIC ACID; VANILLOID RECEPTOR;

BEHAVIOR THERAPY; CHRONIC DISEASE; CHRONIC LIVER DISEASE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG MEGADOSE; EVENING DOSAGE; HODGKIN DISEASE; HUMAN; KIDNEY FAILURE; LOW DRUG DOSE; LYMPHOMA; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PHOTOTHERAPY; PREVALENCE; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PRURITUS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SENSITIZATION; TREATMENT INDICATION; TREATMENT RESPONSE; ULTRAVIOLET B RADIATION;

ANALGESICS; ANTIPRURITICS; CHRONIC DISEASE; HUMANS; KIDNEY FAILURE, CHRONIC; LIVER DISEASES; LYMPHOMA; PRURITUS;

EID: 73149122735     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2009.04249.x     Document Type: Review

References (123)

1. Ständer S, Weisshaar E, Mettang T. Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol 2007, 87:291-294.
2. Yosipovitch G, Greaves MW, Schmelz M. Itch. Lancet 2003, 361:690-694.
3. Yosipovitch G, Greaves MW, Yosipovitch G, Greaves MW, Fleischer AB, McGlone F. Definitions of itch. Itch: Basic Mechanisms and Therapy 2004, In, eds, New York, Marcel Dekker, p
4. Polat M, Oztas P, Ilhan MN. Generalized pruritus: a prospective study concerning etiology. Am J Clin Dermatol 2008, 9:39-44.
5. Duque MI, Thevarajah S, Chan YH. Uremic pruritus is associated with higher Kt/V and serum calcium concentration. Clin Nephrol 2006, 66:184-191.
6. Pisoni RL, Wikström B, Elder SJ. Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2006, 21:3495-3505.
7. Kurban MS, Boueiz A, Kibbi AG. Cutaneous manifestations of chronic kidney disease. Clin Dermatol 2008, 26:255-264.
8. Robinson BE. Epidemiology of chronic kidney disease and anemia. J Am Med Dir Assoc 2006, 7(9 Suppl):S3-S6. quiz S17-21
9. Rishe E, Azarm A, Bergasa NV. Itch in primary biliary cirrhosis: a patients' perspective. Acta Derm Venereol 2008, 88:34-37.
10. Gobbi PG, Attardo-Parrinello G, Lattanzio G. Severe pruritus should be a B-symptom in Hodgkin's disease. Cancer 1983, 51:1934-1936.
11. Kumar SS, Kuruvilla M, Pai GS. Cutaneous manifestations of non-Hodgkin's lymphoma. Indian J Dermatol Venereol Leprol 2003, 69:12-15.
12. Rubenstein M, Duvic M. Cutaneous manifestations of Hodgkin's disease. Int J Dermatol 2006, 45:251-256.
13. Patel T, Freedman B, Yosipovitch G. An update on pruritus associated with CKD. Am J Kidney Dis 2007, 50:11-20.
14. Germain M. Correlation between uremic pruritus intensity and quality of life: a report from the ITCH National Registry. Am Soc Nephrol 2008, Abstract TH-PO798
15. Kremer AE, Beuers U, Oude-Elferink RP, Pusl T. Pathogenesis and treatment of pruritus in cholestasis. Drugs 2008, 68:2163-2182.
16. Saray Y, Seçkin D, Bilezikçi B. Acquired perforating dermatosis: clinicopathological features in twenty-two cases. J Eur Acad Dermatol Venereol 2006, 20:679-688.
17. Kay J. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction. Ann Rheum Dis 2008, 67(Suppl 3):iii66-iii69.
18. Bergasa NV, Mehlman JK, Jones EA. Pruritus and fatigue in primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol 2000, 14:643-655.
19. Pusl T, Beuers U. Ursodeoxycholic acid treatment of vanishing bile duct syndromes. World J Gastroenterol 2006, 12:3487-3495.
20. Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 2000, 31:1005-1013.
21. Neuberger J, Jones EA. Liver transplantation for intractable pruritus is contraindicated before an adequate trial of opiate antagonist therapy. Eur J Gastroenterol Hepatol 2001, 13:1393-1394.
22. Winkelmann RK, Rajka G. Atopic dermatitis and Hodgkin's disease. Acta Derm Venereol 1983, 63:176-177.
23. Denman ST. A review of pruritus. J Am Acad Dermatol 1986, 14:375-392.
24. Schmelz M, Schmidt R, Bickel A. Specific C-receptors for itch in human itch. J Neurosci 1997, 17:8003-8008.
25. Andrew D, Craig AD. Spinothalamic lamina I neurons selectively sensitive to histamine: a central neural pathway for itch. Nat Neurosci 2001, 4:72-77.
26. Shelley WB, Arthur RP. Studies on cowhage (Mucuna pruriens) and its pruritogenic proteinase, mucunain. AMA Arch Derm 1955, 72:399-406.
27. Davidson S, Zhang X, Yoon CH. The itch-producing agents histamine and cowhage activate separate populations of primate spinothalamic tract neurons. J Neurosci 2007, 27:10007-10014.
28. Namer B, Carr R, Johanek LM. Separate peripheral pathways for pruritus in man. J Neurophysiol 2008, 100:2062-2069.
29. Johanek LM, Meyer RA, Friedman RM. A role for polymodal C-fiber afferents in nonhistaminergic itch. J Neurosci 2008, 28:7659-7669.
30. Ward L, Wright E, McMahon SB. A comparison of the effects of noxious and innocuous counterstimuli on experimentally induced itch and pain. Pain 1996, 64:129-138.
31. Yosipovitch G, Duque MI, Fast K. Scratching and noxious heat stimuli inhibit itch in humans: a psychophysical study. Br J Dermatol 2007, 156:629-634.
32. Ikoma A, Ikoma A, Fartasch M. Painful stimuli evoke in patients with chronic pruritus: central sensitization for itch. Neurology 2004, 62:212-217.
33. Ishiuji Y, Coghill RC, Patel TS. Repetitive scratching and noxious heat do not inhibit histamine-induced itch in atopic dermatitis. Br J Dermatol 2008, 158:78-83.
34. Zhang YH, Nicol GD. NGF-mediated sensitization of the excitability of rat sensory neurons is prevented by a blocking antibody to the p75 neurotrophin receptor. Neurosci Lett 2004, 366:187-192.
35. Dou YC, Hagströmer L, Emtestam L. Increased nerve growth factor and its receptors in atopic dermatitis: an immunohistochemical study. Arch Dermatol Res 2006, 298:31-37.
36. Tokime K, Katoh-Semba R, Yamanaka K. Enhanced production and secretion of glial cell line-derived neurotrophic factor and nerve growth factor from the skin in atopic dermatitis mouse model. Arch Dermatol Res 2008, 300:343-352.
37. Ishiuji Y, Coghill RC. The brain processing of scratching in patients with atopic eczema. J Invest Dermatol 2008, 128:S13. Supplement 1, Abstract 75
38. Thurmond RL, Gelfand EW, Dunford PJ. The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discov 2008, 7:41-53.
39. Bell JK, McQueen DS, Rees JL. Involvement of histamine H4 and H1 receptors in scratching induced by histamine receptor agonists in Balb C mice. Br J Pharmacol 2004, 142:374-380.
40. Dunford PJ, Williams KN, Desai PJ. Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J Allergy Clin Immunol 2007, 119:176-183.
41. Rossbach K, Wendorff S, Sander K. Histamine H4 receptor antagonism reduces hapten-induced scratching behaviour but not inflammation. Exp Dermatol 2009, 18:57-63.
42. Wang H, Fan YM, Ru LQ. Involvement of histamine 3 receptor in 5-HT-induced itch in rats. J Am Acad Dermatol 2007, 56(Suppl 2):AB45.
43. Sugimoto Y, Iba Y, Nakamura Y. Pruritus-associated response mediated by cutaneous histamine H3 receptors. Clin Exp Allergy 2004, 34:456-459.
44. Steinhoff M, Neisius U, Ikoma A. Protease-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci 2003, 23:6176-6180.
45. Reddy B. Cowhage-evoked itch is mediated by a novel cysteine protease: a ligand of protease-activated receptors. J Neurosci 2008, 28:4331-4335.
46. Bodo E, Kovacs I, Telek A. Vanilloid receptor-1 (VR1) is widely expressed on various epithelial and mesenchymal cell types of human skin. J Invest Dermatol 2004, 123:410-413.
47. Stander A, Moormann C, Schumacher M. Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structure. Exp Dermatol 2004, 13:129-139.
48. Bíró T, Tóth BI, Marincsák R. TRP channels as novel players in the pathogenesis and therapy of itch. Biochim Biophys Acta 2007, 1772:1004-1021.
49. Shim WS, Tak MH, Lee MH. TRPV1 mediates histamine-induced itching via the activation of phospholipase A2 and 12-lipoxygenase. J Neurosci 2007, 27:2331-2337.
50. Yoshioka T, Imura K, Asakawa M. Impact of the Gly573Ser substitution in TRPV3 on the development of allergic and pruritic dermatitis in mice. J Invest Dermatol 2009, 129:714-722.
51. Sun YG, Chen ZF. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature 2007, 448:700-703.
52. Fjellner B, Hagermark O. Potentiation of histamine-induced itch and flare responses in human skin by the enkaphalin analogue FK-33-824, beta-endorphin and morphine. Arch Dermatol Res 1982, 274:29-37.
53. Fjellner B, Hagermark O. The influence of the opiate antagonist naloxone on experimental pruritus. Acta Derm Venereol 1984, 64:73-75.
54. Hagermark O. Peripheral and central mediators of itch. Skin Pharmacol 1992, 5:1-8.
55. Bernstein JE, Swift R. Relief of intractable pruritus with naloxone. Arch Dermatol 1979, 115:1366-1367.
56. Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. BMJ 1988, 297:1501-1504.
57. Spivey JR, Jorgensen RA, Gores GJ. Methionine-enkephalin concentrations correlate with stage of disease but not pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 1994, 89:2028-2032.
58. Swain MG, Rothman RB, Xu H. Endogenous opioids accumulate in plasma in a rat model of acute cholestasis. Gastroenterology 1992, 103:630-635.
59. Bergasa NV, Vergalla J, Swain MG. Hepatic concentrations of proenkaphalin-derived opioids are increased in a rat model of cholestasis. Liver 1996, 16:298-302.
60. Bergasa NV, Sabol SL, Young WS. Cholestasis is associated with preproenkephalin mRNA expression in the adult rat liver. Am J Physiol 1995, 268:G346-G354.
61. Bergasa NV, Liau S, Homel P. Hepatic Met-enkephalin immunoreactivity is enhanced in primary biliary cirrhosis. Liver 2002, 22:107-113.
62. Kumagai H, Saruta T, Matsukawa S, Yosipovitch G, Greaves MW, Fleischer JA, McGlone F. Prospects for a novel kappa-opioid receptor agonist, TRK-820, in uremic pruritus. Itch, Basic Mechanisms and Therapy 2004, 279-286. In, eds, New York, NY, Dekker, pp
63. Wikström B, Gellert R, Ladefoged SD. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 2005, 16:3742-3747.
64. Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol 2006, 54:527-531.
65. Yosipovitch G, Papoiu AD. What causes itch in atopic dermatitis? Curr Allergy Asthma Rep 2008, 8:306-311.
66. Sonkoly E, Muller A, Lauerma AI. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006, 117:411-417.
67. Grimstad O, Sawanobori Y, Vestergaard C. Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis. Exp Dermatol 2009, 18:35-43.
68. Kimmel M, Alscher DM, Dunst R. The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients. Nephrol Dial Transplant 2006, 21:749-755.
69. Yosipovitch G, Fleischer A. Itch associated with skin disease: advances in pathophysiology and emerging therapies. Am J Clin Dermatol 2003, 4:617-622.
70. Ibrahim MM, Porreca F, Lai J. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A 2005, 102:3093-3098.
71. Hermann H, Petrocellis L, Bisogno T. Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1 receptor-mediated response. Cell Mol Life Sci 2003, 60:607-616.
72. Borgeat A, Wilder-Smith OH, Mentha G. Subhypnotic doses of propofol relieve pruritus associated with liver disease. Gastroenterology 1993, 104:244-247.
73. Prieto LN. The use of midazolam to treat itching in a terminally ill patient with biliary obstruction. J Pain Symptom Manage 2004, 28:531-532.
74. Mettang T, Pauli-Magnus C, Alscher DM. Uraemic pruritus-New perspectives and insights from recent trials. Nephrol Dial Transplant 2002, 17:1558-1563.
75. Gilchrest BA, Rowe JW, Brown RS. Ultraviolet phototherapy of uremic pruritus: long-term results and possible mechanism of action. Ann Intern Med 1979, 91:17-21.
76. Pauli-Magnus C, Klumpp S, Alscher DM. Short-term efficacy of tacrolimus ointment in severe uremic pruritus. Perit Dial Int 2000, 20:802-803.
77. Kuypers DR, Claes K, Evenepoel P. A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy. Nephrol Dial Transplant 2004, 19:1895-1901.
78. Silva SR, Viana PC, Lugon NV. Thalidomide for the treatment of uremic pruritus: A crossover randomized double-blind trial. Nephron 1994, 67:270-273.
79. Razeghi E, Tavakolizadeh S, Ahmadi F. Inflammation and pruritus in hemodialysis patients. Saudi J Kidney Dis Transpl 2008, 19:62-66.
80. Stahle-Backdahl M. Uremic pruritus: clinical and experimental studies. Acta Derm Venereol Suppl (Stockh) 1989, 145:S1-S38.
81. Fantini F, Baraldi A, Sevignani C. Cutaneous innervation in chronic renal failure patients: an immunohistochemical study. Acta Derm Venereol 1992, 77:102-105.
82. Yosipovitch G, Yarnitsky D, Mermelstein V. Paradoxical heat sensation in uremic polyneuropathy. Muscle Nerve 1995, 18:768-771.
83. Momose A, Kudo S, Sato M. Calcium ions are abnormally distributed in the skin of haemodialysis patients with uraemic pruritus. Nephrol Dial Transplant 2004, 19:2061-2066.
84. Morton CA, Lafferty M, Hau C. Pruritus and skin hydration during dialysis. Nephrol Dial Transplant 1996, 11:2031-2036.
85. Bencini PL, Montagnino G, Citterio A. Cutaneous abnormalities in uremic patients. Nephron 1985, 40:316-321.
86. Ostlere LS, Taylor C, Baillod R. Relationship between pruritus, transepidermal water loss, and biochemical markers of renal itch in haemodialysis patients. Nephrol Dial Transplant 1994, 9:1302-1304.
87. Yosipovitch G, Tur E, Morduchowicz G. Skin surface pH, moisture, and pruritus in haemodialysis patients. Nephrol Dial Transplant 1993, 8:1129-1132.
88. Yosipovitch G, Duque MI, Patel TS. Skin barrier structure and function and their relationship to pruritus in end-stage renal disease. Nephrol Dial Transplant 2007, 22:3268-3272.
89. Zucker I, Yosipovitch G, David M. Prevalence and characterization of uremic pruritus in patients undergoing hemodialysis: Uremic pruritus is still a major problem for patients with end-stage renal disease. J Am Acad Dermatol 2003, 49:842-846.
90. Stapelbroek JM, van Erpecum KJ, Klomp LW. Nasobiliary drainage induces long-lasting remission in benign recurrent intrahepatic cholestasis. Hepatology 2006, 43:51-53.
91. Beuer U, Gerken G, Pusl T. Biliary drainage transiently relieves intractable pruritus in primary biliary cirrhosis. Hepatology 2006, 44:280-281.
92. Murphy GM, Ross A, Billing BH. Serum bile acids in primary biliary cirrhosis. Gut 1972, 13:201-206.
93. Bartholomew TC, Summerfield JA, Billing BH. Bile acid profiles of human serum and skin interstitial fluid and their relationship to pruritus studied by gas chromatography-mass spectrometry. Clin Sci (Lond) 1982, 63:65-73.
94. Swain MG, Neuberger J. Pruritus and lethargy in the primary biliary cirrhosis patients. Primary Biliary Cirrhosis 1999, 75-81. In, ed, Eastbourne, West End Studios
95. Kimata H, Lindley I. Detection of plasma interleukin-8 in atopic dermatitis. Arch Dis Child 1994, 70:119-122.
96. Biggar RJ, Johansen JS, Smedby KE. Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma. Clin Cancer Res 2008, 14:6974-6978.
97. Lee HL, Eom HS, Yun T. Serum and urine levels of interleukin-8 in patients with non-Hodgkin's lymphoma. Cytokine 2008, 43:71-75.
98. Ständer S, Bockenholt B, Schürmeyer-Horst F. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. Acta Derm Venereol 2009, 89:45-51.
99. Yosipovitch G, Samuel LS. Neuropathic and psychogenic itch. Dermatol Ther 2008, 21:32-41.
100. Yosipovitch G, Carstens E, McGlone F. Chronic itch and chronic pain. Analogous mechanisms. Pain 2007, 131:4-7.
101. Hundley JL, Yosipovitch G. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study. J Am Acad Dermatol 2004, 50:889-891.
102. Davis MP, Frandsen JL, Walsh D. Mirtazapine for pruritus. J Pain Symptom Manage 2003, 25:288-291.
103. Summey BT, Yosipovitch G. Pharmacologic advances in the systemic treatment of itch. Dermatol Ther 2005, 18:328-332.
104. Patel T, Ishiuji Y, Yosipovitch G. Nocturnal itch: why do we itch at night? Acta Derm Venereol 2007, 87:295-298.
105. Tandon P, Rowe BH, Vandermeer B. The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol 2007, 102:1528-1536.
106. Pauli-Magnus C, Mikus G, Alscher DM. Naltrexone does not relieve uremic pruritus: results of a randomised placebo-controlled study. J Am Soc Nephrol 2000, 11:514-519.
107. Peer G, Kivity S, Agami O. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet 1996, 349:1552-1554.
108. Inan S, Cowan A. Nalfurafine. A kappa opioid receptor agonist, inhibits scratching behavior secondary to cholestasis induced by chronic ethynylestradiol injections in rats. Pharmacol Biochem Behav 2006, 85:39-43.
109. Carter J, Zug KA. Phototherapy for cutaneous T-cell lymphoma: online survey and literature review. J Am Acad Dermatol 2009, 60:39-50.
110. Gunal AI, Ozalp G, Yoldas TK. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant 2004, 19:3137-3139.
111. Manenti L, Vaglio A, Costantino E. Gabapentin in the treatment of uremic itch: an index case and a pilot evaluation. J Nephrol 2005, 18:86-91.
112. Duque MI, Yosipovitch G, Fleischer AB. Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study. J Am Acad Dermatol 2005, 52(3 Pt 1):519-521.
113. Chen ZJ, Gao G, Tang WX. A randomized controlled trial of high-permeability haemodialysis against conventional haemodialysis in the treatment of uraemic pruritus. Clin Exp Dermatol 2009, Epub ahead of print. Jan 23
114. Szepietowski JC, Szepietowski T, Reich A. Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study. Acta Dermatovenerol Croat 2005, 13:97-103.
115. Cho YL, Liu HN, Huang TP. Uremic pruritus: roles of parathyroid hormone and substance P. J Am Acad Dermatol 1998, 38:503-504.
116. Young TA, Patel TS. A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients. J Dermatolog Treat 2009, 20:76-81.
117. Dinler G, Kocak N. Ursodeoxycholic acid therapy in children with cholestatic liver disease. Turk J Pediatr 1999, 41:91-98.
118. Talwalkar JA, Souto E, Jorgensen RA. Natural history of pruritus in primary biliary cirrohsis. Clin Gastroenterol Hepatol 2003, 1:297-302.
119. Yerushalmi B, Sokol RJ, Narkewicz MR. Use of rifampin for severe pruritus in children with chronic cholestasis. J Pediatr Gastroenterol Nutr 1999, 29:442-447.
120. Mayo MJ, Handem I, Saldana S. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 2007, 45:666-674.
121. Steiner C, Mitzner S. Experiences with MARS liver support therapy in liver failure: analysis of 176 patients of the International MARS Registry. Liver 2002, 22(Suppl 2):20-25.
122. Bergasa NV, McGee M, Ginsburg IH. Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. Hepatology 2006, 44:1317-1323.
123. Demierre MF, Taverna J. Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma. J Am Acad Dermatol 2006, 55:543-544.